Diagnosing Hair Loss in Women
Hair loss in women can have several underlying causes, and identifying the correct condition is essential before beginning treatment. The most common cause of progressive patterned thinning is female pattern hair loss, also known as androgenetic alopecia. However, excessive shedding, autoimmune disorders, hormonal changes, nutritional deficiencies, inflammatory scalp conditions and certain medications can also contribute to hair loss. In some women, more than one condition is present at the same time.
A diagnosis should begin with a careful examination of the scalp and hair, together with a detailed medical history. The pattern of thinning, duration of shedding, family history, reproductive and hormonal history, medication use, recent illness, nutritional changes and scalp symptoms such as itching, burning, pain, redness or scaling can provide important clues. Women who report that their hair loss began after starting, changing or discontinuing hormonal contraception should also have that history carefully considered.
It is equally important to distinguish hair shedding from hair breakage. Shedding involves the release of hairs from the follicle as part of the hair growth cycle, while breakage occurs when the hair shaft becomes damaged and fractures. Although both can produce a noticeable reduction in hair volume, their underlying causes and treatment approaches may differ.
One of the most important distinctions is between telogen effluvium, a condition characterized by increased shedding, and androgenetic alopecia, which involves the progressive miniaturization of susceptible hair follicles. Although these conditions are different, they can occur together. A woman experiencing significant shedding may have underlying female pattern hair loss that has gone unrecognized, while a diagnosis of chronic telogen effluvium may sometimes be assigned without adequately investigating evidence of follicular miniaturization.
The absence of an obvious receding hairline or bald spot does not rule out androgenetic alopecia. Many women experience diffuse thinning, a widening central part or a gradual reduction in hair volume long before their hair loss becomes visually pronounced. Others continue to shed excessively while their remaining hair becomes progressively finer. These changes deserve careful evaluation, particularly when thinning persists despite normal laboratory results.
Normal blood tests do not rule out female pattern hair loss. Many women with androgenetic alopecia do not have elevated circulating androgen levels or an identifiable hormonal disorder. The diagnosis is often made through the combination of medical history, scalp examination and evidence of follicular miniaturization rather than through blood testing alone.
Not every woman requires an extensive panel of laboratory investigations or invasive diagnostic procedures. Testing should be selected according to the individual’s symptoms, examination findings and medical history. Unnecessary testing can create confusion and expense without improving the diagnosis, while inadequate examination can delay recognition of progressive or potentially permanent forms of hair loss.
Diagnostic Tests:
Hormone Levels
Hormonal evaluation should be guided by the patient’s clinical presentation, medical history and the judgment of a qualified healthcare professional. Assessment for androgen excess is particularly important when hair loss is accompanied by irregular menstrual periods, significant acne, excessive facial or body hair growth, infertility or other features suggesting an endocrine disorder.
Depending on the clinical findings, testing may include total or free testosterone, dehydroepiandrosterone sulfate (DHEA-S), androstenedione, prolactin and other selected hormones. Follicle-stimulating hormone (FSH), luteinizing hormone (LH) and additional reproductive hormone tests may be useful in particular circumstances, but they are not routinely necessary for every woman experiencing hair loss.
Hormonal contraceptives can influence androgen levels and other laboratory measurements, making the timing and interpretation of testing important. A woman’s reproductive history, menstrual patterns and current medications should therefore be considered when deciding which investigations are appropriate.
It is essential to understand that female pattern hair loss frequently occurs in women whose hormone levels are entirely normal. The absence of a measurable hormonal abnormality should never be used as a reason to dismiss progressive thinning or exclude androgenetic alopecia.
Serum Iron and Ferritin
Iron deficiency can contribute to excessive hair shedding, particularly in women with heavy menstrual bleeding, restricted diets or other conditions affecting iron intake or absorption. Serum ferritin is primarily a marker of the body’s stored iron, while serum iron provides information about circulating iron.
Low ferritin levels may support a diagnosis of iron deficiency, but they do not necessarily establish that iron deficiency is the primary cause of hair loss. Likewise, a normal ferritin level does not rule out androgenetic alopecia or other hair disorders. Ferritin results must be interpreted in context because inflammation and certain medical conditions can elevate ferritin independently of iron stores.
Iron supplementation should be based on appropriate medical evaluation rather than the assumption that increasing iron intake will improve hair growth. Excessive iron supplementation can be harmful, and there is no universally established ferritin target that guarantees improvement in hair density.
Total Iron Binding Capacity (TIBC)
Total iron binding capacity measures the blood’s capacity to bind and transport iron through the protein transferrin. It may be ordered alongside serum iron, ferritin and transferrin saturation when iron deficiency or another disorder of iron metabolism is suspected.
These measurements can help clarify whether inadequate iron availability may be contributing to shedding, particularly when initial results are uncertain. However, iron studies should be interpreted together with the patient’s medical history and clinical findings rather than as a stand-alone explanation for hair loss.
Thyroid Function Tests (TSH, Free T4 and Selected Additional Tests)
Both an underactive thyroid and an overactive thyroid can affect the normal hair growth cycle and contribute to diffuse shedding or changes in hair texture. Thyroid disorders may also produce symptoms such as fatigue, unexplained weight changes, temperature intolerance, menstrual irregularities and changes in skin condition.
Thyroid-stimulating hormone (TSH) is commonly used as the initial screening test for thyroid dysfunction. Free thyroxine (free T4) and, in selected circumstances, triiodothyronine (T3) or other thyroid-related tests may be appropriate depending on the patient’s symptoms and initial findings.
An abnormal thyroid result may help identify a contributing medical condition, but it does not automatically explain every aspect of a woman’s hair loss. Androgenetic alopecia and thyroid disease can coexist, and treating a thyroid disorder may not reverse thinning caused by progressive follicular miniaturization.
VDRL
Syphilis testing may be appropriate in selected patients when their medical history, symptoms or examination findings raise concern for infection. The Venereal Disease Research Laboratory (VDRL) test is one of several blood tests used in the evaluation of syphilis, an infection that can occasionally cause hair loss. Syphilitic alopecia may produce patchy or diffuse shedding and can sometimes resemble other hair loss disorders.
Testing for syphilis is not a routine requirement for every woman experiencing hair loss. Modern evaluation may involve alternative or additional syphilis tests, depending on the testing approach used by the healthcare provider.
When an infectious cause is suspected, identifying and treating the underlying infection is essential rather than attempting to manage the resulting hair loss in isolation.
Complete Blood Count (CBC)
A complete blood count measures several components of the blood, including red blood cells, white blood cells, hemoglobin and platelets. It can help identify anemia or other abnormalities that may warrant additional investigation.
A CBC may be especially useful when hair shedding occurs alongside fatigue, heavy menstrual bleeding, nutritional concerns or symptoms suggesting an underlying medical condition. However, a normal CBC does not exclude low iron stores, and an abnormal result does not necessarily establish why a woman is losing her hair.
Blood testing should support the clinical evaluation, not replace a careful examination of the scalp and hair.
Scalp Biopsy
A scalp biopsy involves removing a small sample of scalp tissue, commonly approximately 4 millimeters in diameter, for microscopic examination. The procedure is performed under local anesthesia and may help distinguish androgenetic alopecia, chronic telogen effluvium, alopecia areata and certain inflammatory or scarring hair loss disorders.
A scalp biopsy is not routinely necessary to diagnose female pattern hair loss and should not be performed simply because a woman is experiencing thinning or excessive shedding. In many cases, androgenetic alopecia can be identified through a careful clinical examination and the detection of follicular miniaturization using trichoscopy, densitometry or systematic miniaturization mapping. When these findings are characteristic of female pattern hair loss, a biopsy may provide little additional diagnostic value.
The American Hair Loss Association believes scalp biopsies are sometimes performed when a careful clinical evaluation and appropriate noninvasive examination could establish the diagnosis. A biopsy should be reserved for situations in which it is likely to provide meaningful additional diagnostic information, particularly when findings are inconclusive or an inflammatory or scarring disorder is suspected. It should not substitute for a thorough examination by a clinician knowledgeable about hair loss.
When a scarring alopecia is suspected, however, a timely biopsy may be especially important. Conditions such as lichen planopilaris, frontal fibrosing alopecia and other inflammatory disorders can permanently destroy hair follicles. Delaying an indicated biopsy or appropriate treatment may allow irreversible damage to continue.
When a biopsy is indicated, the location from which the tissue is obtained is critically important. The sample must be selected to answer the specific diagnostic question, which may require examining an actively affected area rather than a severely depleted or inactive region. In certain cases, more than one sample or specialized tissue processing may be appropriate.
Equally important is the experience of the physician interpreting the specimen. Hair follicle pathology requires specialized knowledge, and the method used to section and examine the tissue can influence what is identified. When the diagnosis is uncertain, evaluation by a dermatopathologist experienced in hair disorders may be especially valuable.
A scalp biopsy can provide important diagnostic evidence, but it is not infallible. Sampling limitations, overlapping conditions and differences in interpretation can affect the result. The findings should always be considered alongside the patient’s history, clinical presentation and other examination results.
Hair Pull Test
The hair pull test is a simple examination used to assess whether a woman is experiencing active hair shedding. The clinician gently draws a small group of hairs, typically approximately 50 to 60 strands, between the fingers and observes how many hairs are released.
An increased number of extracted hairs may suggest active shedding, as can occur with telogen effluvium and certain other hair loss conditions. However, the result depends on several factors, including the timing of hair washing, recent grooming and whether the shedding is currently active.
A negative hair pull test does not rule out androgenetic alopecia. Women with progressive follicular miniaturization may have little or no excessive shedding during the examination, even while their hair density continues to decline. The test is therefore most useful when interpreted alongside the overall pattern of thinning and findings from scalp examination.
Densitometry
Hair densitometry uses magnification or specialized imaging to evaluate characteristics of the hair and scalp, including hair shaft diameter and differences in hair thickness. One of its most important applications is identifying follicular miniaturization, a defining feature of androgenetic alopecia.
In women with female pattern hair loss, hairs in affected areas may vary considerably in diameter, with an increasing proportion of finer, miniaturized hairs. By systematically examining and comparing hair shaft miniaturization in different regions of the scalp, a clinician can identify patterns consistent with androgenetic alopecia, often before substantial thinning becomes visually apparent.
This systematic approach, sometimes described as miniaturization mapping, can be performed using appropriate magnification or digital imaging techniques. It is not a separate, universally standardized diagnostic test, but rather a method of evaluating the distribution and extent of follicular miniaturization across the scalp.
More advanced digital imaging systems may also measure hair density, hair shaft thickness and other parameters over time. These measurements can be useful for documenting progression or assessing response to treatment, although results can vary according to the equipment, technique and consistency of the examination.
Densitometry is an assessment tool rather than a diagnosis by itself. Its findings should be interpreted within the broader clinical evaluation, particularly when a woman may have more than one cause of hair loss. In straightforward cases of androgenetic alopecia, however, characteristic miniaturization findings may provide sufficient diagnostic evidence without the need for a scalp biopsy.
Scalp Dermoscopy (Trichoscopy)
Trichoscopy is one of the most valuable noninvasive tools available for diagnosing hair and scalp disorders. It uses magnification, often through a handheld dermoscope or digital video system, to examine hair shafts, follicular openings and the surrounding scalp in greater detail than is possible with the naked eye.
In female pattern hair loss, trichoscopy can reveal variation in hair shaft diameter, an increased proportion of miniaturized hairs and differences in hair density between affected and relatively unaffected areas. These findings can be particularly useful in women whose hair loss is still in its early stages or who have been told that their thinning is simply the result of stress or chronic shedding.
Unlike densitometry, which focuses primarily on measuring or comparing hair characteristics, trichoscopy also allows a broader examination of the scalp for features associated with alopecia areata, traction alopecia, hair shaft damage and inflammatory or scarring disorders. Findings such as perifollicular scaling, redness, loss of follicular openings or other signs of inflammation may indicate a condition requiring further investigation and prompt treatment.
The technique is particularly important when distinguishing chronic telogen effluvium from androgenetic alopecia. While telogen effluvium generally produces increased shedding without the characteristic progressive miniaturization of pattern hair loss, a woman may have both conditions simultaneously. The presence, extent and distribution of miniaturized hairs can therefore substantially change the diagnostic assessment, even when the most noticeable symptom is excessive shedding.
Although trichoscopy is highly useful, no single finding establishes every diagnosis with certainty. The examination must be interpreted by a knowledgeable clinician in conjunction with the patient’s medical history, scalp findings and, when appropriate, laboratory testing or biopsy.
The AHLA Perspective
The American Hair Loss Association believes that one of the greatest problems facing women with hair loss is not simply the limited number of effective treatments, but the failure to identify the underlying condition accurately and early enough. For decades, the AHLA has encountered women who spent years being told that their thinning was caused by stress, aging, nutritional deficiencies or temporary hormonal changes, only to discover that progressive androgenetic alopecia had been developing throughout that period.
Of particular concern is the diagnosis of chronic telogen effluvium in women who may actually have female pattern hair loss, or both conditions simultaneously. Persistent shedding should not automatically lead to a diagnosis of chronic telogen effluvium without a careful assessment for follicular miniaturization. Normal hormone levels, normal laboratory tests and the absence of obvious bald spots do not rule out androgenetic alopecia.
The AHLA is also concerned about the unnecessary use of diagnostic procedures when a woman’s hair loss can be accurately identified through noninvasive examination. In straightforward cases of androgenetic alopecia, careful clinical assessment, trichoscopy and systematic evaluation of miniaturization may provide the information needed without a scalp biopsy. At the same time, a biopsy should never be delayed when there is a legitimate concern about a scarring or inflammatory condition that could permanently damage hair follicles.
Women also deserve a thorough consideration of their hormonal and medication histories, including the initiation, modification or discontinuation of hormonal contraceptives. Although these associations do not establish causation, they can provide important clues that deserve serious clinical attention rather than dismissal.
Another significant concern is the growing availability of commercial hair loss evaluations that focus primarily on selling products, supplements or procedures rather than establishing an accurate diagnosis. A sophisticated-looking scalp scan, a laboratory panel or a consultation at a hair restoration clinic does not necessarily constitute a comprehensive medical assessment. The value of any diagnostic technology depends on how its findings are interpreted and whether they meaningfully contribute to identifying the underlying disorder.
For women with progressive thinning, an accurate diagnosis can determine whether treatment is likely to preserve existing hair, whether additional medical investigation is necessary or whether a particular intervention is inappropriate. For women with inflammatory or scarring disorders, prompt diagnosis may be essential to preventing permanent follicular destruction.
The AHLA’s position is that women experiencing hair loss deserve more than reassurance, assumptions, unnecessary procedures or an endless succession of products promising regrowth. They deserve knowledgeable medical evaluation, clear explanations of their diagnosis and realistic guidance about what can and cannot be achieved with treatment. Hair loss can have a profound emotional and psychological impact, and the importance of getting the diagnosis right should never be underestimated.